Notable life science industry activity for this coverage week: FDA approvals, clinical trial milestones, funding rounds, grants, and deals. Pulled from public industry data, not personalized to any one company or account.
This week was a grab bag without a clean thread, which happens. A couple of specialty approvals landed alongside the usual steady stream of generics, and one company made a geographic move that points to where antiviral manufacturing is heading. Nothing here is a surprise, but a few details are worth noticing if you're watching market access or the companies that handle manufacturing and distribution.
Gilead won priority review approval for Hepcludex on May 22, a treatment for hepatitis delta virus, a serious liver infection that only shows up in people who already have hepatitis B. It's a narrow market, but it's also one with almost no other options, which tends to matter for both pricing and the specialist manufacturers who handle harder-to-make therapies. Priority review means the FDA moved faster than usual, which usually signals the agency saw something clinically meaningful.
Galderma moved an acne gel from prescription to over-the-counter on May 22, which expands who can buy it but also shifts how it's sold and distributed. That's a different kind of commercial event than a new drug approval, and it leans toward retail and consumer channels rather than the specialty networks. Meanwhile, the generics approvals kept rolling. Rubicon, Steranco, and Alembic all landed approvals for older drugs in the central nervous system and thyroid space. These are high-volume, low-margin products that keep the behind-the-scenes manufacturers busy. Lupin, separately, received approval in China for an oseltamivir suspension, an antiviral for influenza, marking the company's entry into the Chinese market. That's the kind of geographic move that tends to pull in contract manufacturers and active pharmaceutical ingredient suppliers. We only see what we happen to pick up, so treat this as a few signals, not the whole board.